Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate with more enthusiasm around their leading products, while relative newcomers also entered the fray as well.
BTIG analysts Marie Thibault and Sam Eiber last year said the diabetes technology field was a “high-priority” space for medtech investors. (Here’s a link to last year’s roundup). They continue to present optimism around the space after this year’s edition.
“The diabetes tech segment of medtech continues to evolve rapidly, with new user populations, payor coverage, and competitive dynamics giving investors numerous catalysts to track,” the analysts wrote. “We remain bullish on the ability for diabetes tech sales growth rates to be well above most medtech peers.”
What news shared at ADA 2024 led to this bullish outlook from the analysts? Here are some of the standout stories from the four-day event:
Abbott has high hopes for the future following latest sensor innovations
Drug Delivery Business News sat down with Abbott Diabetes SVP of Commercial Operations, Chris Scoggins, at ADA to discuss the latest developments at the company.
With the recent FDA clearance of two over-the-counter sensors following significant automated insulin pump integrations, 2024 has been full of good news for the company. Scoggins expects the good times to continue to roll.
Get the full story at our sister site, Drug Delivery Business News.
